# BioPharm International > BioPharm International - Healthcare Publication - Base URL: https://www.biopharminternational.com - Generated: 2026-10-20T23:58:42.018Z - Content updates: multiple times daily ## Content Access for AI Agents This site supports content negotiation for AI/LLM consumption. Request any article URL with an appropriate Accept header to receive structured content instead of HTML. **Supported content types:** - `text/markdown` — Clean Markdown with YAML frontmatter - `text/plain` — Plain text (same as Markdown) - `text/html` — Default HTML response **Example request:** ``` curl -H "Accept: text/markdown" https://www.biopharminternational.com/view/article-slug ``` **YAML frontmatter schema** (returned with every Markdown response): | Field | Type | Description | |-------|------|-------------| | `title` | string | Article headline | | `description` | string | Summary/excerpt (max 300 chars) | | `url` | string | Canonical article URL | | `canonical_url` | string | Canonical URL if different from `url` | | `published` | ISO 8601 | Original publication date | | `modified` | ISO 8601 | Last modification date | | `authors` | string[] | Author display names | | `content_type` | string | Content category (e.g., "News", "Clinical") | | `categories` | string[] | Taxonomy categories | | `tags` | string[] | SEO tags | | `image` | string | Featured image URL | | `publisher` | string | Publication/site name | **Discovery headers** (included on all responses): - `Link: ; rel="llms"` — RFC 8288 link to this file - `X-Llms-Txt: https://www.biopharminternational.com/llms.txt` — Explicit discovery header ## Usage Policy - Robots policy: [https://www.biopharminternational.com/robots.txt](https://www.biopharminternational.com/robots.txt) - Cache behavior: responses are cached for ~5 minutes (max-age=300, stale-while-revalidate=329) - Rate guidance: prefer RSS and sitemap feeds over crawling individual pages - Attribution: All content © MJH Life Sciences. Include source URLs when citing. ## Content Categories - [Avantor](https://www.biopharminternational.com/avantor) - [Behind the Headlines](https://www.biopharminternational.com/behind-the-headlines) - [BioPharm Videos](https://www.biopharminternational.com/biopharm-videos) - [COVID-19 Update](https://www.biopharminternational.com/covid-19-update) - [Drug Digest](https://www.biopharminternational.com/drug-digest) - [Editorial Podcasts](https://www.biopharminternational.com/editorial-podcasts) - [Events](https://www.biopharminternational.com/events) - [News](https://www.biopharminternational.com/news) - [Sponsored Podcasts](https://www.biopharminternational.com/sponsored-podcasts) - [Sponsored Videos](https://www.biopharminternational.com/sponsored-videos) - [Topic](https://www.biopharminternational.com/topic) - [Video Series](https://www.biopharminternational.com/video-series) - [Webcasts](https://www.biopharminternational.com/webcasts) - [Whitepapers](https://www.biopharminternational.com/whitepapers) ## Featured Content - [The BioPharm Brief: Lung Injury Survival, Alzheimer Prevention, and Longer Dosing Intervals](https://www.biopharminternational.com/view/the-biopharm-brief-lung-injury-survival-alzheimer-prevention-and-longer-dosing-intervals): Nano24’s inhaled exosome therapy reduces mortality in a phase 2b ARDS trial, the FDA grants fast track designation to Nuravax’s preventive Alzheimer v... - [METiS TechBio, Lilly Partner on AI-Designed LNPs for Tissue-Specific Delivery](https://www.biopharminternational.com/view/metis-techbio-lilly-partner-on-ai-designed-lnps-for-tissue-specific-delivery): METiS TechBio will apply its AI-driven AiLNP ionizable lipid platform to discover LNPs designed to deliver therapeutics beyond the liver, under a coll... - [Bionyra’s Long-Acting Anti-TL1A Antibody BYN-002 Shows Roughly 80-Day Half-Life in Phase 1](https://www.biopharminternational.com/view/bionyra-s-long-acting-anti-tl1a-antibody-byn-002-shows-roughly-80-day-half-life-in-phase-1): Interim phase 1 data presented at UEG Week 2026 showed Bionyra Pharma’s Fc-engineered anti-TL1A antibody BYN-002 suppressed soluble TL1A with a half-l... - [Nano24's Inhaled EXO-CD24 Cuts ARDS Mortality in Phase 2b Trial](https://www.biopharminternational.com/view/nano24-inhaled-exo-cd24-ards-phase-2b-mortality): Inhaled EXO-CD24 kept 85% of patients with ARDS free of respiratory failure at day 7 vs 33.3% with placebo in a 90-patient phase 2b trial. - [Nuravax Alzheimer Vaccine AV-1959R Earns FDA Fast Track Designation](https://www.biopharminternational.com/view/nuravax-av-1959r-alzheimer-vaccine-fda-fast-track): Nuravax will test AV-1959R in a 160-adult phase 2 trial to see whether the amyloid vaccine can prevent Alzheimer disease before symptoms begin. - [AAPS Names Patrick Sinko Chief Science Officer Ahead of PharmSci 360 2026](https://www.biopharminternational.com/view/aaps-names-patrick-sinko-chief-science-officer-ahead-of-pharmsci-360-2026): The American Association of Pharmaceutical Scientists appointed former president Patrick J. Sinko as chief science officer to lead its scientific stra... - [The BioPharm Brief: New Approval, Pediatric Progress, and Durable Remission](https://www.biopharminternational.com/view/the-biopharm-brief-new-approval-pediatric-progress-and-durable-remission): The FDA grants accelerated approval to dostarlimab for rectal cancer, Lilly reports one-year remission data for pediatric ulcerative colitis, and John... - [Dostarlimab-gxly Wins FDA Accelerated Approval in Rectal Cancer](https://www.biopharminternational.com/view/dostarlimab-fda-accelerated-approval-rectal-cancer): Accelerated approval for dostarlimab-gxly (Jemperli) pairs a single-arm phase 2 dataset with an FDA-authorized biomarker test and confirmatory require... - [Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says](https://www.biopharminternational.com/view/biomarker-testing-gaps-targeted-oncology-therapy-bms-pennell): BMS's Dr Nathan Pennell outlines how biomarker testing barriers and trial diversity affect patient access to targeted oncology drugs. - [Lilly’s Omvoh Reaches 50% One-Year Remission in Pediatric Ulcerative Colitis](https://www.biopharminternational.com/view/lilly-s-omvoh-reaches-50-one-year-remission-in-pediatric-ulcerative-colitis): In the phase 3 SHINE-2 trial, half of pediatric patients who responded to mirikizumab induction were in clinical remission at week 52. Lilly plans to... ## Feeds and Indexes - [RSS Feed](https://www.biopharminternational.com/rss.xml): Latest articles in XML syndication format - [Sitemap](https://www.biopharminternational.com/sitemap.xml): Complete URL index for all published pages - [News Sitemap](https://www.biopharminternational.com/sitemap-news.xml): Recent articles optimized for news indexing - [Authors Directory](https://www.biopharminternational.com/authors): Browse all contributors and their published work